Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | YES1 | P07947 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469947 | 0.94 | AVPR1B (0.41) | SRCKDRLCKMAPK14AVPR1B | |
| SCHEMBL6469154 | 0.90 | KDR (0.40) | HRH3KDRAVPR1B | |
| SCHEMBL6469230 | 0.90 | PDK2 (0.37) | HRH3AVPR1BKCNH2 | |
| SCHEMBL6469215 | 0.90 | KDR (0.41) | KDRAVPR1B | |
| Trifluoroacetic Acid SCHEMBL6470902 | 0.89 | HRH3 (0.42) | HRH3SRCKDRLCKMAPK14 | |
| SCHEMBL6467386 | 0.89 | TDP2 (0.36) | — | |
| SCHEMBL6470081 | 0.88 | NPSR1 (0.37) | — | |
| SCHEMBL6469079 | 0.88 | MCHR1 (0.36) | HRH3KDRKCNH2 | |
| SCHEMBL6468687 | 0.87 | EHMT2 (0.43) | HRH3KDRAVPR1BKCNH2 | |
| SCHEMBL6466094 | 0.85 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | claimed |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | HRH3 638/4885SRC 4282/4885KDR 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.